Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
Citations

WEB OF SCIENCE

10
Citations

SCOPUS

9

초록

Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible without medical intervention in the early stage, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, eventually, cirrhosis and hepatic cancer. The progression of NAFLD is related to various factors such as genetics, pre-disposed metabolic disorders, and immunologic factors. Thankfully, to date, there have been accumulating research efforts and, as a result, different classes of potent drug candidates have been discovered. In addition, there have also been various attempts to explore pharmaceutical strategies to improve the druggability of drug candidates. In this review, we provided a brief overview of the drug candidates that have undergone clinical trials. In the latter part, strategies for developing better drugs are discussed.

키워드

nonalcoholic fatty liver diseasenonalcoholic steatohepatitisfibrosiscirrhosisstrategiesGLUCAGON-LIKE PEPTIDE-1HEPATIC STELLATE CELLSDOUBLE-BLINDBETA-KLOTHOMOUSE MODELHALF-LIFERECEPTORAGONISTSTEATOHEPATITISEFFICACY
제목
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
저자
Amatya, ReejuLee, DongheeMin, Kyoung AhShin, Meong Cheol
DOI
10.3390/pharmaceutics15071963
발행일
2023-07
유형
Review
저널명
Pharmaceutics
15
7